<DOC>
	<DOCNO>NCT02097134</DOCNO>
	<brief_summary>This pilot clinical trial study whether unilateral group D retinoblastoma , retinoblastoma affect one eye spread inner jelly like part eye , treat new technique deliver chemotherapy directly blood vessel supply affect eye . This new technique call intra-arterial injection . This may give child unilateral retinoblastoma low chance need surgery remove eye reduce amount treatment side effect .</brief_summary>
	<brief_title>Intra-arterial Melphalan Treating Younger Patients With Unilateral Retinoblastoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To study feasibility deliver melphalan directly ophthalmic artery child newly diagnose unilateral group D retinoblastoma , would otherwise consider enucleation . SECONDARY OBJECTIVES : I . To estimate ocular salvage rate treatment intra-arterial melphalan child newly diagnose unilateral retinoblastoma group D disease . II . To evaluate toxicity adverse event associate deliver multiple dos intra-arterial chemotherapy . III . To evaluate vision outcome child treat intra-arterial chemotherapy . IV . To monitor rate development metastatic disease protocol therapy . TERTIARY OBJECTIVES : I . To evaluate effect intra-arterial therapy histopathology eye enucleate progression . OUTLINE : Patients receive melphalan intra-arterially ( IA ) day 1 . Treatment repeat every 28 day 3 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year , every 4 month 1 year , every 6 month 1 year , periodically 2 year .</detailed_description>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Nitrogen Mustard Compounds</mesh_term>
	<criteria>Newly diagnose patient unilateral group D retinoblastoma Magnetic resonance imaging ( MRI ) ( compute tomography [ CT ] MRI available ) brain must perform within 14 day prior study entry Diagnostic examination anesthesia ( EUA ) must perform within 14 day prior study entry Rapid central review confirmation group D disease base RetCam image diagnostic EUA must obtain start treatment Patients must performance status correspond Eastern Cooperative Oncology Group ( ECOG ) score 0 , 1 2 Patients must life expectancy &gt; = 8 week Patients must adequate renal function , define : Creatinine clearance radioisotope glomerular filtration rate ( GFR ) &gt; = 70 mL/min/1.73 m^2 A serum creatinine base age/gender follow : 1 month &lt; 6 month : 0.4 mg/dL 6 month &lt; 1 year : 0.5 mg/dL 1 &lt; 2 year : 0.6 mg/dL 2 &lt; 6 year : 0.8 mg/dL 6 &lt; 10 year : 1 mg/dL 10 &lt; 13 year : 1.2 mg/dL 13 &lt; 16 year : 1.5 mg/dL ( male ) ; 1.4 mg/dL ( female ) &gt; = 16 year : 1.7 mg/dL ( male ) ; 1.4 mg/dL ( female ) Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) age Serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase ( ALT ) ) &lt; 2.5 x upper limit normal ( ULN ) age Patients bilateral disease Unilateral retinoblastoma group A , B , C , E eye Prior chemotherapy radiation therapy disease ( laser cryotherapy allow consider exclusion criterion ) Clinical neuroimaging evidence extraocular disease orbital optic nerve involvement</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>